Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients
Autor
Mondelo-Macía, Patricia
García-González, Jorge
Abalo, Alicia
Mosquera-Presedo, Manuel
Aguín, Santiago
Mateos, María
López-López, Rafael
León-Mateos, Luis
Muinelo-Romay, Laura
Díaz-Peña, Roberto
Resumen
Background: Lack of biomarkers for treatment selection and monitoring in small cell lung cancer (SCLC) patients with the limited therapeutic options, result in poor outcomes. Therefore, new prognostic biomarkers are needed to improve their management. The prognostic value of cell-free DNA (cfDNA) and circulating tumor cells (CTCs) have been less explored in SCLC. Methods: We quantified cfDNA in 46 SCLC patients at different times during first-line of chemotherapy or chemo-immunotherapy. Moreover, CTCs were analyzed in 21 patients before therapy onset using CellSearch® system. The possible association between both biomarkers and patients' outcomes was investigated in order to develop a prognostic model. Results: High cfDNA levels before therapy were associated with shorter progression-free survival (PFS) and overall survival (OS). Furthermore, cfDNA levels at 3 weeks and at progression disease were also associated with patients' outcomes. Multivariate analyses confirmed the independence of cfDNA levels as a prognostic biomarker. Finally, the three-risk category prognostic model developed included Eastern Cooperative Oncology Group Performance Status (ECOG PS), gender and baseline cfDNA levels was associated with a higher risk of progression and death. Conclusions: We confirmed the prognostic utility of cfDNA quantitative analysis in SCLC patients before and during therapy. Our novel risk prognostic model in clinical practice will allow to identify patients who could benefit with actual therapies. © 2022 AME Publishing Company. All rights reserved.
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy (2020)
Brozos-Vázquez, Elena María; Díaz-Peña, Roberto; García-González, Jorge; Leon Mateos, Luis; Mondelo-Macía, Patricia; Peña-Chilet, María; López-López, Rafael (Springer Science and Business Media Deutschland GmbH, 2020-10-28)Immunotherapy has been one of the great advances in the recent years for the treatment of advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that has benefited most from this approach. Currently, ... -
Article
Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study (2024)
Rapado-González, Óscar; Brea-Iglesias, Jenifer; Rodríguez-Casanova, Aitor; Bao-Caamano, Aida; López-Cedrún, José-Luis; Triana-Martínez, Gabriel; Díaz-Peña, Roberto; Santos, María Arminda; López-López, Rafael; Muinelo-Romay, Laura; ... (John Wiley and Sons Inc, 2023)Background: We explore the utility of TruSight Tumor 170 panel (TST170) for detecting somatic mutations in tumor and cfDNA from locoregional recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Methods: ... -
Article
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 (2024)
Ong, Kanyin Liane; Stafford, Lauryn K.; McLaughlin, Susan A.; Boyko, Edward J.; Vollset, Stein Emil; Smith, Amanda E.; Dalton, Bronte E.; Duprey, Joe; Cruz, Jessica A.; Hagins, Hailey; ... (Elsevier B.V., 2023)Background: Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global ...